Clinical trials: Dendritic Cell
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Glioma, Brain Cancer
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
DC vaccine manufactured and partially matured using our standard operating procedures, developed in collaboration with the HGG Immuno Group, then administered through imiquimod treated skin will be safe and feasible in children…
- Conditions
- Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme
- Trial name
- NCT01902771
- Testing
- Dendritic Cell Vaccine, Tumor Lysate, Imiquimod
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Edward Ziga
Prostate Cancer
A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA
Purpose: This protocol proposes a safety and feasibility trial in patients with metastatic prostate cancer (stages D1-D3) investigating the induction of antitumor immunity by administration of cultured autologous peripheral blood…
- Trial name
- NCT00006430
- Testing
- Autologous dendritic cells transfected with amplified tumor RNA
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Breast Cancer
Immunotherapy in Treating Patients With Metastatic Breast Cancer
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells.
- Trial name
- NCT00003432
- Testing
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Colorectal Neoplasms
Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer
The different alternatives used since 1996 to treat metastatic colorectal cancer (MCRC) have increased the mean survival of these patients.
- Trial name
- NCT01413295
- Testing
- Dendritic Cell Vaccine, Supportive treatment
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Cancer of the Prostate
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
The main aim of this trial is to assess the response rate, the feasibility and toxicity of the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients.
- Trial name
- NCT01897207
- Testing
- Dendritic cell application
- Volunteers
- 15 people
- Sponsor
- Cantonal Hospital of St. Gallen
Gastric Cancer
Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
Study objectives are to investigate the efficacy and safety of activated autologous dendritic cells (DCs) in treatment of gastric cancer.
- Trial name
- NCT03410732
- Testing
- activated DCs, radical surgery only
- Where
- China
- Volunteers
- 120 people
- Sponsor
- LanZhou University
Kidney Transplant Rejection
Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients
The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant…
- Trial name
- ATDC-PICI (NCT06852625)
- Testing
- Autologous Tolerogenic Dendritic Cells
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Psoriasis Vulgaris, Psoriasis
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Psoriasis is a non-communicable chronic immune-mediated disease. Psoriatic skin is characterized by excessive proliferation of skin cells and infiltration of immune cells. The cause of psoriasis is so far unknown.
- Conditions
- Psoriasis Vulgaris, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- MEMPSOLAR (NCT05185258)
- Testing
- Enstilar
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aarhus University Hospital
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00126685
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen
Melanoma
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study to evaluate safety and immune responses, with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs)…
- Trial name
- NCT00515983
- Testing
- DC/Apo-Nec
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- José Mordoh, M.D., Ph.D.
Colorectal Cancer
Study of DC-CIK to Treat Colorectal Cancer
The purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
- Trial name
- NCT01839539
- Testing
- dendritic and cytokine-induced killer cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Cancer, Hematologic Malignancies
Consolidation Therapy in Patients With Hematologic Malignancies
The purpose of this study is to determine the safety and efficacy of Tumor Associated Peptide Antigen (TAPA) pulsed dendritic cell (DC) vaccines in the treatment of hematologic malignancies.
- Trial name
- NCT02709993
- Testing
- TAPA-pulsed DC vaccine
- Where
- United States
- Sponsor
- Kiromic BioPharma Inc.
Glioblastoma
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
Phase I/II clinical trial on the per-operative intra-tumoral administration of myeloid dendritic cells plus ipilimumab and nivolumab, followed by repeated intracavitary administration of ipilimumab and nivolumab plus intravenous…
- Trial name
- GlitIpNi (NCT03233152)
- Testing
- Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution), Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myDC
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
This study is for subjects with a type of skin cancer called melanoma. The main purpose of this study is to examine the safety of the study drug (Poly-ICLC) in patients with your disease.
- Trial name
- NCT01783431
- Testing
- Poly ICLC, leukapheresis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Sarcoma, Central Nervous System Tumor
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with…
- Trial name
- DEND/TIA (NCT02496520)
- Testing
- dendritic cells, Surgery as needed by the patient´s tumor and stage, Chemotherapy as needed by the patient´s tumor and stage
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Pancreatic Adenocarcinoma Non-resectable
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma.
- Trial name
- NCT01677962
- Testing
- Poly-ICLC, dendritic cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina